2013
DOI: 10.1089/thy.2012.0455
|View full text |Cite
|
Sign up to set email alerts
|

Columnar Cell Variant of Papillary Thyroid Carcinoma: A Study of 10 Cases with Emphasis on CDX2 Expression

Abstract: Only one of our cases showed nuclear positivity for CDX2. Therefore, our study failed to confirm it as a marker for CCV-PTC. The absence of CDX2 in the majority of the cases does not support the theory of CDX2 playing a role in the intestinal phenotype of these tumors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
28
0
2

Year Published

2013
2013
2019
2019

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(30 citation statements)
references
References 21 publications
0
28
0
2
Order By: Relevance
“…CDX2 may be positive in up to 50% of CCV, but it is not expressed in other benign or malignant thyroid lesions . BRAF V600E is found in one‐third of CCV cases …”
Section: Aggressive Variants Of Ptcmentioning
confidence: 99%
“…CDX2 may be positive in up to 50% of CCV, but it is not expressed in other benign or malignant thyroid lesions . BRAF V600E is found in one‐third of CCV cases …”
Section: Aggressive Variants Of Ptcmentioning
confidence: 99%
“…Carcinoembryonic antigen and TTF1 immunohistochemistry are helpful in distinguishing columnar cell variant PTC from metastatic adenocarcinoma of the colon because columnar cell variant PTC is negative for carcinoembryonic antigen and variably positive for TTF1. However, immunocytochemistry for estrogen receptor and CDX2 (intestinal‐type differentiation marker) are not useful because they have been found to be positive in some columnar cell variant PTC . The prognosis of columnar cell variant PTC was revised in the current WHO classification .…”
Section: Columnar Cell Variant Ptcmentioning
confidence: 99%
“…However, immunocytochemistry for estrogen receptor and CDX2 (intestinaltype differentiation marker) are not useful because they have been found to be positive in some columnar cell variant PTC. [118][119][120][121] The prognosis of columnar cell variant PTC was revised in the current WHO classification. 1 Encapsulated columnar cell variant PTC has indolent biological behavior, but cases with extrathyroid extension demonstrate aggressive clinical behavior and have a less favorable prognosis 118,122 (Table 2).…”
Section: Columnar Cell Variant Ptcmentioning
confidence: 99%
“…Eighty-three cases of CCV-PTC have been described in the PubMed database. [6][7][8][9][10][11][12][13][14][15][16][17] There were 57 women and 27 men including our case. The age ranged from 16 to 90 years at an average of 51, which is older than that of the classic PTC with an average age of 43.…”
Section: Previous Studies Of Ccv-ptcmentioning
confidence: 99%